Dr. Enrico Garaci
Biography & Research Background
Enrico Garaci, MD, is affiliated with the University San Raffaele Roma and the Istituto Superiore di Sanita. He pioneered combination experimental protocol strategies using Thymosin Alpha 1 with chemotherapy (cyclophosphamide) and cytokines (IL-2, IFN) for cancer and infectious diseases. His landmark studies demonstrated synergy achieving complete tumor regression in leukemia and lung carcinoma models, and his 2007 historical overview in the Annals of the New York Academy of Sciences remains a cornerstone reference for the field. Enrico Garaci is being referenced as one of the leading scientists involved in the research and development of Thymosin Alpha 1. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
Dr. Enrico Garaci is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Dr. Enrico Garaci is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.